secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-05-15T20:01:51+00:00
Accession:  0001625297-26-000024
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Indivior eliminates Chief Scientific Officer role; Heidbreder to depart Dec 31, 2026
--------------------------------------------------------------------------------

- CSO position eliminated effective June 1, 2026; Dr. Christian Heidbreder transitions to advisory role through year-end.
- Heidbreder's employment terminates Dec 31, 2026 as a termination without cause per existing agreement.
- At May 13 annual meeting, shareholders elected all eight director nominees with overwhelming support.
- Say-on-pay approved; frequency set to annual until 2032 unless board changes.
- Ratification of PwC as independent auditor for fiscal 2026 passed with 99.1M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000024/0001625297-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529726000024/indv-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001625297-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer